Ken Suzawa

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Helena A. Yu, Ken Suzawa, Emmet Jordan et al. · Clinical Cancer Research · 2018 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Ken Suzawa, Michael Offin, Daniel Lu et al. · Clinical Cancer Research · 2018 · 120 citations

Medicine, Oncology, Pharmacology +15

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Morana Vojnic, Daisuke Kubota, Christopher Kurzatkowski et al. · Journal of Thoracic Oncology · 2019 · 97 citations · Full text

Medicine, Genetics, Oncology +12

Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib

Shinsuke Hashida, Hiromasa Yamamoto, Kazuhiko Shien et al. · Cancer Science · 2015 · 83 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring <i> <scp>HER</scp> 2 </i> oncogene alterations

Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi et al. · Cancer Science · 2015 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17